Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab as adjuvant therapy after nephrectomy for high-risk renal cell carcinoma
NL-OMON55502Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Atezolizumab with Placebo (2 arms). Primary endpoint: Investigator-assessed disease-free survival. Started Oct 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON55502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55502.